2'-fluoronucleosides
AssigneesUniversity of Georgia Research Foundation, Inc., Emory University
InventorsRAYMOND F. SCHINAZI, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee
Life of this patent
Estimating the term…
Loading patent…
AssigneesUniversity of Georgia Research Foundation, Inc., Emory University
InventorsRAYMOND F. SCHINAZI, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee
Estimating the term…
2′-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.
-47. (canceled)
A method for the treatment of a HCV infection in a host in need thereof comprising administering an effective treatment amount of a β-D-2′-fluoronucleoside wherein the 2′-fluoro of the β-D-2′-fluoronucleoside is alpha (α), or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.
A method for the treatment of a HCV infection in a host in need thereof comprising administering an effective treatment amount of a β-D-2′-α-fluoronucleoside, or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.
Dependencies are inferred from the claim text.